Skip to content

News items:


  • Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.

    Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.

    We are happy to announce our newest team member to join Cyclomics. With a background in Biology, Rita Ferreira holds a PhD degree in Medical Microbiology (2022) from the University of Groningen. Rita’s expertise in cell and molecular biology will contribute to the design and implementation of novel molecular assays and the overall development of… Read More »Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.

    Read full news article


  • Cyclomics finalizes Oncode clinical proof-of-concept project

    Cyclomics finalizes Oncode clinical proof-of-concept project

    Our technology, CyclomicsSeq, has been used in a recent Clinical Proof-of-Concept(Cpoc) project funded by the Oncode Institute. In this project several patients with advanced head and neck cancer were monitored over several months to obtain information about responders and non-responders for the given treatment. The project was performed in collaboration with the Netherlands Cancer Institute… Read More »Cyclomics finalizes Oncode clinical proof-of-concept project

    Read full news article


  • Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium

    Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium

    Cyclomics’ CSO Wigard Kloosterman presented the CyclomicsSeq technology at the online Cancer Research Symposium organised by Oxford Nanopore Technologies. The recording of the presentation is now available online. The presentation covers details of the CyclomicsSeq technology, which enables consensus sequencing of DNA fragments using the Oxford Nanopore sequencing instruments. Cyclomics aims at delivering flexible, accurate… Read More »Cyclomics presents technology at Oxford Nanopore Cancer Research Symposium

    Read full news article


  • Cyclomics announces publication on CyclomicsSeq technology

    Cyclomics announces publication on CyclomicsSeq technology

    We are excited to announce the publication about Cyclomics’ core CyclomicsSeq technology in Genomic Medicine.  CyclomicsSeq technology involves a novel consensus sequencing approach fully optimised for circulating tumor DNA. The small size and low abundance of circulating tumor DNA in the blood of cancer patients makes accurate detection of cancer mutations difficult. Cyclomics has established a… Read More »Cyclomics announces publication on CyclomicsSeq technology

    Read full news article


  • Appointment of Dàmi Rebergen as bioinformatician at Cyclomics

    Appointment of Dàmi Rebergen as bioinformatician at Cyclomics

    We are happy to announce the appointment of Dàmi Rebergen to strengthen the bioinformatics capabilities of Cyclomics. Dàmi Rebergen has a bioinformatics degree from Wageningen University (2019) and has recent experience working at startup and biotech companies in The Netherlands and the UK. At Cyclomics, Dàmi will perform a key role in the establishment of a… Read More »Appointment of Dàmi Rebergen as bioinformatician at Cyclomics

    Read full news article


  • CyclomicsSeq manuscript available as preprint

    CyclomicsSeq manuscript available as preprint

    We are happy to announce the publication of our preprint manuscript about CyclomicsSeq on biorxiv.org. The manuscript describes our technology for capturing, amplifying, and high-accuracy sequencing of short circulating tumor DNA molecules from patients with cancer. We have developed CyclomicsSeq to be compatible with any long-read DNA sequencer and have extensively tested the technology with… Read More »CyclomicsSeq manuscript available as preprint

    Read full news article


  • Cyclomics and University Medical Center Utrecht sign collaboration agreement

    Cyclomics and University Medical Center Utrecht sign collaboration agreement

    Following the licensing of liquid biopsy technology owned by the University Medical Center Utrecht (UMC Utrecht), Cyclomics and the UMC Utrecht have entered into a long-standing collaboration to strengthen the synergy between both parties further, and drive technological innovation and clinical evaluation of the CyclomicsSeq platform technology. The agreement is an essential milestone for Cyclomics… Read More »Cyclomics and University Medical Center Utrecht sign collaboration agreement

    Read full news article


  • Cyclomics mentioned on Nature Methods

    Cyclomics mentioned on Nature Methods

    Cyclomics was mentioned in Nature Methods Technology Feature The high-impact scientific journal Nature Methods has mentioned the Cyclomics founding team and technology in a recent article on Nanopore sequencing. The paper provides a historical overview of developments in Oxford Nanopore sequencing technology. One of the striking features of the Oxford Nanopore MinION instrument is the… Read More »Cyclomics mentioned on Nature Methods

    Read full news article


  • Cyclomics highlighted on GenomeWeb

    Cyclomics highlighted on GenomeWeb

    A recent article on the most read genomics news website, has featured an interview with Cyclomics founders Alessio Marcozzi and Jeroen de Ridder. The news item – which can be read in full on GenomeWeb – provides a comprehensive overview of the CyclomicsSeq technology for detection of cancer mutations in circulating tumor DNA. The article… Read More »Cyclomics highlighted on GenomeWeb

    Read full news article


  • Cyclomics presents at LC 2019

    Cyclomics presents at LC 2019

    During the yearly London Calling conference, organised by Oxford Nanopore Technologies, Cyclomics CEO Jeroen de Ridder reported on recent results obtained from their CyclomicsSeq platform. The London Calling conference is a yearly event, that attracts over 600 academic and industrial researchers, who use the Oxford Nanopore sequencing platform for applications ranging from genome research, pathogen… Read More »Cyclomics presents at LC 2019

    Read full news article


  • Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.

    We are happy to announce our newest team member to join Cyclomics. With a background in Biology, Rita Ferreira holds a PhD degree in Medical Microbiology (2022) from the University of Groningen. Rita’s expertise in cell and molecular biology will contribute to the design and implementation of novel molecular assays and the overall development of… Read More »Appointment of Rita Ferreira as Molecular Biology Scientist at Cyclomics.